123 related articles for article (PubMed ID: 35112382)
1. Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP-ribose) polymerase inhibitor, in subjects with advanced solid cancers.
Bian Y; Meng J; Ma S; Li G; Wang Y; Li S; Liu L; Huang C; Zhang H; Zhong D; Miao L
Br J Clin Pharmacol; 2022 Jul; 88(7):3307-3320. PubMed ID: 35112382
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of absorption, distribution, metabolism, and excretion of [
Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ
Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355
[TBL] [Abstract][Full Text] [Related]
3. Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers.
Chen X; Yang F; Zhao J; Tang Q; Heng J; Deng J; Zhang J; Chen Y; Li K; Wang J
Cancer Chemother Pharmacol; 2022 Jan; 89(1):141-148. PubMed ID: 34851444
[TBL] [Abstract][Full Text] [Related]
4. Human mass balance study and metabolite profiling of
van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Lucas L; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH
Invest New Drugs; 2017 Dec; 35(6):751-765. PubMed ID: 28303528
[TBL] [Abstract][Full Text] [Related]
5. Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects.
Hu L; Dou T; Sun Q; Tang L; Cai M; Qian W; Wang H
Invest New Drugs; 2023 Apr; 41(2):276-283. PubMed ID: 36800130
[TBL] [Abstract][Full Text] [Related]
6. A randomized, open-label, two-period crossover bridging study on fuzuloparib capsules of different specifications in healthy Chinese volunteers.
Jiang X; Tao Y; Liu Y; Shi P; Li T; Sun F; Cao Y; Wang C
Br J Clin Pharmacol; 2022 Mar; 88(3):1087-1093. PubMed ID: 34378245
[TBL] [Abstract][Full Text] [Related]
7. Human Mass Balance and Metabolite Profiling of [
Mu S; Palmer D; Fitzgerald R; Andreu-Vieyra C; Zhang H; Tang Z; Su D; Sahasranaman S
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1108-1120. PubMed ID: 33876576
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study.
Tiseo PJ; Perdomo CA; Friedhoff LT
Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):19-24. PubMed ID: 9839761
[TBL] [Abstract][Full Text] [Related]
9. Biotransformation of [
Pusalkar S; Plesescu M; Gupta N; Hanley M; Venkatakrishnan K; Wu JT; Xia C; Zhang X; Chowdhury S
Cancer Chemother Pharmacol; 2018 Nov; 82(5):803-814. PubMed ID: 30128949
[TBL] [Abstract][Full Text] [Related]
10. Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers.
Hu C; Zhang Y; Pei T; Liu P; Zhang L
Cancer Chemother Pharmacol; 2023 Jun; 91(6):523-529. PubMed ID: 37166499
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, Mass Balance and Metabolism of [
Yuan JJ; Bian YC; Ma S; Chen W; Zhang FY; Zhang H; Miao LY
Eur J Drug Metab Pharmacokinet; 2023 Nov; 48(6):723-731. PubMed ID: 37833493
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.
Nijenhuis CM; Lucas L; Rosing H; Huitema ADR; Mergui-Roelvink M; Jamieson GC; Fox JA; Mould DR; Schellens JHM; Beijnen JH
Invest New Drugs; 2017 Aug; 35(4):478-490. PubMed ID: 28138829
[TBL] [Abstract][Full Text] [Related]
13. Mass balance and pharmacokinetics of an oral dose of
Dai X; Karol MD; Hitron M; Hard ML; Blanchard JE; Eraut NCJE; Rich N; Gufford BT
Pharmacol Res Perspect; 2021 Feb; 9(1):e00722. PubMed ID: 33576192
[TBL] [Abstract][Full Text] [Related]
14. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [
Zhou X; Pusalkar S; Chowdhury SK; Searle S; Li Y; Ullmann CD; Venkatakrishnan K
Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836
[TBL] [Abstract][Full Text] [Related]
15. Fuzuloparib: First Approval.
Lee A
Drugs; 2021 Jul; 81(10):1221-1226. PubMed ID: 34118019
[TBL] [Abstract][Full Text] [Related]
16. The impact of rifampicin on the pharmacokinetics of fuzuloparib in healthy Chinese male volunteers.
Zhang Q; Kai J; Zhai Y; Xu N; Shentu J; Zhang Y; Liang Y; Wang Y; Wu L
Br J Clin Pharmacol; 2022 Jan; 88(1):84-90. PubMed ID: 34033139
[TBL] [Abstract][Full Text] [Related]
17. Tolerability, safety, and preliminary antitumor activity of fuzuloparib in combination with SHR-1316 in patients with relapsed small cell lung cancer: a multicenter, open-label, two-stage, phase Ib trial.
Xu Y; Huang Z; Fang J; Liu A; Lu H; Yu X; Chen K; Xu X; Ma X; Shi W; Kim YH; Hakozaki T; Addeo A; Shen Y; Li S; Fan Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1069-1078. PubMed ID: 35832454
[TBL] [Abstract][Full Text] [Related]
18. Mass balance, pharmacokinetics and pharmacodynamics of intravenous HSK3486, a novel anaesthetic, administered to healthy subjects.
Bian Y; Zhang H; Ma S; Jiao Y; Yan P; Liu X; Ma S; Xiong Y; Gu Z; Yu Z; Huang C; Miao L
Br J Clin Pharmacol; 2021 Jan; 87(1):93-105. PubMed ID: 32415708
[TBL] [Abstract][Full Text] [Related]
19. Effect of food on the pharmacokinetics and safety profiles of a new PARP inhibitor fuzuloparib capsules in healthy volunteers.
Du P; Long Y; Wang M; Huang Y; Wang Y; Chen X; Lin Y; Wu J; Shen J; Jia Y
Cancer Chemother Pharmacol; 2024 May; ():. PubMed ID: 38703321
[TBL] [Abstract][Full Text] [Related]
20. Mass balance, metabolic disposition, and pharmacokinetics of [
Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
